Current Report Filing (8-k)
11 January 2023 - 8:16AM
Edgar (US Regulatory)
0001499785
false
00000
0001499785
2023-01-09
2023-01-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
and Exchange Act of 1934
Date of Report (date of earliest event reported):
January 9, 2023
Tengjun Biotechnology Corp.
(Exact name
of registrant as specified in its charter)
| Nevada |
|
333-169397 |
|
27-3042462 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
| of incorporation) |
|
|
|
Identification Number) |
East Jinze Road and South Huimin Road, Food
Industry Economic and Technology Development District,
Jinxiang County, Jining City, Shandong Province,
China
(Address
of principal executive offices and zip code)
(86) 0537-8711599
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name
or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered: |
| None |
|
None |
|
None |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On
January 9, 2023, Tengjun Biotechnology Corp. (the “Company”) conducted its initial closing of the public offering of its common
stock (the “Initial Closing”) pursuant to the Company’s registration statement on Form S-1 (File No. 333-266300) initially
filed with the Securities and Exchange Commission (“Commission”) on July 22, 2022 and declared effective on November 4, 2022
(the “Registration Statement”), whereby the Company offered and sold 3,000,000 shares of common stock (the “Shares”)
at $1.00 per share for a total purchase price of $3,000,000 (the “Initial Closing Amount”) from the investors. The Initial
Closing Amount equals to the minimum offering amount as set forth in the Registration Statement. The Company may conduct additional closings
of this public offering from time to time in the future within the timeframe as described in the Registration Statement.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunder duly authorized.
| Date: January 10, 2023 |
|
|
| |
|
|
| |
Tengjun Biotechnology Corp. |
| |
|
| |
By: |
/s/ Xianchang Ma |
| |
|
Xianchang Ma |
| |
|
Chief Executive Officer |
2
Tengjun Biotechnology (CE) (USOTC:TJBH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Tengjun Biotechnology (CE) (USOTC:TJBH)
Historical Stock Chart
From Nov 2023 to Nov 2024
